Enspryng subcutaneous injection 120mg syringe, manufactured by Chugai Pharmaceutical, contains Satralizumab (genetical recombination). This injectable drug (YJ code: 6399428G1024) is supplied as 120mg in 1mL per tube and is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive.
Enspryng subcutaneous injection 120mg syringe
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →